New drug combo shows promise for High-Risk throat cancer patients
NCT ID NCT02973386
First seen Feb 05, 2026 · Last updated Jun 11, 2026 · Updated 22 times
Summary
This study tested whether adding an extra chemotherapy drug (capecitabine) after standard treatment helps people with advanced nasopharyngeal cancer that is likely to spread. 294 patients received either standard chemoradiotherapy alone or standard treatment plus capecitabine. The goal was to see if the combination could delay the cancer from spreading to other parts of the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCAL ADVANCED HIGH RISK NASOPHARYNGEAL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cancer Center, Sun Yat-sen University
Guangzhou, Guangdong, China
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.